In:
European Journal of Haematology, Wiley, Vol. 97, No. 3 ( 2016-09), p. 253-260
Kurzfassung:
A phase I/ II trial to assess safety and efficacy of the combination bendamustine, rituximab, and lenalidomide ( BRL ) in patients with chronic lymphocytic leukemia ( CLL ). Patients and Methods Seventeen relapsed or refractory (R/R) and five previously untreated ( FL ) CLL patients were enrolled in the trial. In the R/R cohort, four different dose levels of lenalidomide (maximum 15 mg/d) were used. In the FL cohort, lenalidomide was dose escalated from 5 mg/d to 15 mg/d. Bendamustine was used at doses of 50 or 90 mg/m 2 for R/R or FL treatment, respectively. 375 mg/m 2 Rituximab were used for the first and 500 mg/m 2 for subsequent treatment courses. Treatment consisted of up to six courses of 28 d. Results The maximal tolerable dose of lenalidomide was 5 mg/d. The response rate was 47.1% in R/R and 60% in FL patients. Median progression‐free survival was 8.0 months. Median overall survival was 22.9 and 12.3 months, respectively, in R/R and FL patients. Grade 3/4 hematological toxicity was observed in 71.4%, and severe infections in 47.6% of patients. Due to high toxicity and low response rate of BRL , the trial was closed prematurely. Conclusion BRL was associated with a high toxicity rate, a high number of treatment interruptions, and a low remission rate. Therefore, BRL cannot be considered an appropriate treatment option for patients with CLL .
Materialart:
Online-Ressource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2016.97.issue-3
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2016
ZDB Id:
2027114-1
